QI
AZN icon

QS Investors’s AstraZeneca AZN Stock Holding History

QS Investors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-50
Closed -$3K – 1925
2016
Q3 		$3K Buy
+50
New +$3.27K ﹤0.01% 1472
2015
Q2 		– Sell
-80
Closed -$5K – 1412
2015
Q1 		$5K Buy
+80
New +$5.56K ﹤0.01% 1377

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

QS Investors's AZN Position: Q4 2016 in Review

QS Investors sold out of AstraZeneca (AZN) in Q4 2016, closing a stake of 50 shares — an estimated $3K sold.

QS Investors first reported a position in AZN in Q1 2015 and held it in 2 quarters. The position peaked at $5K in Q1 2015. 450 funds tracked by Wall St. Rank hold AZN as of Q4 2016.

  • QS Investors reported no remaining AstraZeneca position as of Q4 2016 after selling out during the quarter.
  • QS Investors sold 50 AstraZeneca shares in Q4 2016, an estimated $3K.
  • QS Investors first reported a position in AstraZeneca in Q1 2015 and held it in 2 quarters.
  • QS Investors's AstraZeneca position peaked at $5K in Q1 2015.
  • 450 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2016.

Based on QS Investors's 13F filing for Q4 2016, filed 14 Feb 2017.